Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|March 29, 2003
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factorSilvia Ferrari, Bianca Rovati, Camillo Porta, et al.
Breast (Edinburgh, Scotland)|December 15, 2010
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issuesAlberto Zambelli, Matteo Giovanni Della Porta, Ermanno Eleuteri, et al.
Oncology Reports|August 9, 2002
Weekly taxanes in metastatic breast cancer (review)Matteo Zimatore, Marco Danova, Erasmo Vassallo, et al.
Oncology|October 16, 2008
Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapyRosangela Invernizzi, Donatella Grasso, Erica Travaglino, et al.
Tumori|May 11, 2006
Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II studyAlberto Riccardi, Silvia Brugnatelli, Marco Danova, et al.
Oncology|July 15, 2005
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findingsMatteo Della Porta, Marco Danova, Gian Matteo Rigolin, et al.
Anticancer Research|December 29, 2010
Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liverGuido Poggi, Emma Pozzi, Alberto Riccardi, et al.
Oncology Reports|March 10, 2005
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patientsCamillo Porta, Ilaria Imarisio, Mara De Amici, et al.
Anticancer Research|May 18, 2012
Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheresCristina Sottani, Guido Poggi, Pietro Quaretti, et al.
Clinical Breast Cancer|December 14, 2011
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trialsMaria Rosa Strada, Raffaella Palumbo, Antonio Bernardo, et al.
Pageof 3